drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01149 | DB11995 | 851 | 1,634 | [
"DDInter1274",
"DDInter143"
] | Nefazodone | Avatrombopag | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Avatrombopag (_Doptelet_), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation,[A33097,L2824] thereby decreasing the need for blood transfusions. Patients with thrombocytopenia and chronic liver disease often require pla... | Moderate | 1 | [
[
[
851,
24,
1634
]
],
[
[
851,
24,
609
],
[
609,
24,
1634
]
],
[
[
851,
63,
254
],
[
254,
24,
1634
]
],
[
[
851,
25,
971
],
[
971,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Avatrombopag"
]
],
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Avatrombopag
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone ... |
DB00687 | DB00783 | 870 | 1,438 | [
"DDInter747",
"DDInter679"
] | Fludrocortisone | Estradiol | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Moderate | 1 | [
[
[
870,
24,
1438
]
],
[
[
870,
63,
1561
],
[
1561,
40,
1438
]
],
[
[
870,
24,
35
],
[
35,
40,
1438
]
],
[
[
870,
6,
2027
],
[
2027,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Estradiol (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol and Quinestrol (Compound) resembles Estradiol... |
DB00564 | DB00619 | 1,236 | 1,419 | [
"DDInter293",
"DDInter909"
] | Carbamazepine | Imatinib | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Major | 2 | [
[
[
1236,
25,
1419
]
],
[
[
1236,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
1236,
21,
28847
],
[
28847,
60,
1419
]
],
[
[
1236,
24,
222
],
[
22... | [
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Imati... | Carbamazepine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Carbamazepine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Imatinib (Compound)
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramin... |
DB01268 | DB12364 | 1,151 | 1,421 | [
"DDInter1731",
"DDInter200"
] | Sunitinib | Betrixaban | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
1151,
24,
1421
]
],
[
[
1151,
63,
1091
],
[
1091,
24,
1421
]
],
[
[
1151,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
1151,
64,
759
],
[
759... | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
... | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatin... |
DB00570 | DB12035 | 147 | 943 | [
"DDInter1936",
"DDInter1641"
] | Vinblastine | Sarecycline | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
147,
24,
943
]
],
[
[
147,
24,
1670
],
[
1670,
24,
943
]
],
[
[
147,
24,
1619
],
[
1619,
63,
943
]
],
[
[
147,
63,
134
],
[
134,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Ruca... |
DB00762 | DB01045 | 613 | 463 | [
"DDInter973",
"DDInter1590"
] | Irinotecan | Rifampicin | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Major | 2 | [
[
[
613,
25,
463
]
],
[
[
613,
64,
690
],
[
690,
40,
463
]
],
[
[
613,
6,
5912
],
[
5912,
45,
463
]
],
[
[
613,
63,
1101
],
[
1101,
... | [
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifampicin"
]
],
[
[
"Irinotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rifabutin"
],
[
"Rifabutin",
"{u} (Co... | Irinotecan may lead to a major life threatening interaction when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Irinotecan (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Rifampicin (Compound)
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken... |
DB00379 | DB00619 | 143 | 1,419 | [
"DDInter1206",
"DDInter909"
] | Mexiletine | Imatinib | Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
143,
24,
1419
]
],
[
[
143,
6,
12523
],
[
12523,
45,
1419
]
],
[
[
143,
21,
28762
],
[
28762,
60,
1419
]
],
[
[
143,
24,
283
],
[
283,... | [
[
[
"Mexiletine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Mexiletine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
... | Mexiletine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Imatinib (Compound)
Mexiletine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Imatinib (Compound)
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib... |
DB00881 | DB06824 | 954 | 29 | [
"DDInter1554",
"DDInter1864"
] | Quinapril | Triethylenetetramine | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta b... | Triethylenetatramine (TETA), also known as trientine, is a potent and selective copper (II)-selective chelator. It is a structural analog of linear polyamine compounds, [spermidine] and [spermine]. TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925. Initially approved... | Moderate | 1 | [
[
[
954,
24,
29
]
],
[
[
954,
23,
1283
],
[
1283,
24,
29
]
],
[
[
954,
23,
286
],
[
286,
63,
29
]
],
[
[
954,
24,
428
],
[
428,
63,
... | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triethylenetetramine"
]
],
[
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
... | Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Triethylenetetramine
Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesi... |
DB09036 | DB09322 | 812 | 1,114 | [
"DDInter1668",
"DDInter1966"
] | Siltuximab | Zinc sulfate | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
812,
23,
1114
]
],
[
[
812,
63,
66
],
[
66,
23,
1114
]
],
[
[
812,
64,
1057
],
[
1057,
23,
1114
]
],
[
[
812,
24,
270
],
[
270,
... | [
[
[
"Siltuximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Siltuximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause ... |
DB01105 | DB13179 | 222 | 68 | [
"DDInter1665",
"DDInter1882"
] | Sibutramine | Troleandomycin | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | A macrolide antibiotic that is similar to erythromycin. | Minor | 0 | [
[
[
222,
23,
68
]
],
[
[
222,
24,
1662
],
[
1662,
24,
68
]
],
[
[
222,
63,
473
],
[
473,
24,
68
]
],
[
[
222,
23,
1619
],
[
1619,
24... | [
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Troleandomycin"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with R... |
DB00366 | DB01221 | 1,594 | 1,190 | [
"DDInter600",
"DDInter1007"
] | Doxylamine | Ketamine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Moderate | 1 | [
[
[
1594,
24,
1190
]
],
[
[
1594,
21,
29339
],
[
29339,
60,
1190
]
],
[
[
1594,
24,
649
],
[
649,
63,
1190
]
],
[
[
1594,
24,
1688
],
[
16... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketamine"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Respiratory depression"
],
[
"Respiratory depression",
"{... | Doxylamine (Compound) causes Respiratory depression (Side Effect) and Respiratory depression (Side Effect) is caused by Ketamine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases... |
DB00029 | DB00461 | 25 | 598 | [
"DDInter99",
"DDInter1254"
] | Anistreplase | Nabumetone | Human tissue plasminogen activator, purified, glycosylated, 527 residues purified from CHO cells. Eminase is a lyophilized (freeze-dried) formulation of anistreplase, the p-anisoyl derivative of the primary Lys-plasminogen-streptokinase activator complex (a complex of Lys-plasminogen and streptokinase). A p-anisoyl gro... | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Moderate | 1 | [
[
[
25,
24,
598
]
],
[
[
25,
25,
366
],
[
366,
24,
598
]
],
[
[
25,
24,
1512
],
[
1512,
63,
598
]
],
[
[
25,
25,
936
],
[
936,
63,
... | [
[
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabumetone"
]
],
[
[
"Anistreplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Epti... | Anistreplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone
Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac ma... |
DB00176 | DB08895 | 529 | 976 | [
"DDInter770",
"DDInter1825"
] | Fluvoxamine | Tofacitinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
529,
24,
976
]
],
[
[
529,
24,
660
],
[
660,
24,
976
]
],
[
[
529,
24,
214
],
[
214,
63,
976
]
],
[
[
529,
25,
39
],
[
39,
25,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib a... |
DB00357 | DB00877 | 1,051 | 629 | [
"DDInter71",
"DDInter1678"
] | Aminoglutethimide | Sirolimus | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
1051,
24,
629
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
629
]
],
[
[
1051,
21,
28921
],
[
28921,
60,
629
]
],
[
[
1051,
24,
907
],
[
907,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v}... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sirolimus (Compound)
Aminoglutethimide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Sirolimus (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00852 | DB01240 | 1,445 | 885 | [
"DDInter1545",
"DDInter657"
] | Pseudoephedrine | Epoprostenol | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1445,
24,
885
]
],
[
[
1445,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1445,
21,
28936
],
[
28936,
60,
885
]
],
[
[
1445,
63,
1252
],
[
1252... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Pseudoephedrine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Epoprostenol (Compound)
Pseudoephedrine ma... |
DB00656 | DB01166 | 827 | 477 | [
"DDInter1851",
"DDInter379"
] | Trazodone | Cilostazol | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
827,
24,
477
]
],
[
[
827,
6,
8374
],
[
8374,
45,
477
]
],
[
[
827,
21,
28892
],
[
28892,
60,
477
]
],
[
[
827,
23,
112
],
[
112,
... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Trazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Trazodone (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Cilostazol (Compound)
Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole ... |
DB00804 | DB01136 | 1,507 | 772 | [
"DDInter543",
"DDInter305"
] | Dicyclomine | Carvedilol | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
1507,
24,
772
]
],
[
[
1507,
6,
9842
],
[
9842,
45,
772
]
],
[
[
1507,
21,
28734
],
[
28734,
60,
772
]
],
[
[
1507,
63,
475
],
[
475,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Dicyclomine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is bound by {v} (Compound)... | Dicyclomine (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Carvedilol (Compound)
Dicyclomine (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Carvedilol (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when t... |
DB00342 | DB00872 | 1,181 | 1,080 | [
"DDInter1770",
"DDInter438"
] | Terfenadine | Conivaptan | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Major | 2 | [
[
[
1181,
25,
1080
]
],
[
[
1181,
24,
165
],
[
165,
40,
1080
]
],
[
[
1181,
63,
1101
],
[
1101,
23,
1080
]
],
[
[
1181,
24,
1374
],
[
1374... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
],
[
"Tolvaptan... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan (Compound) resembles Conivaptan (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limi... |
DB01242 | DB05381 | 1,237 | 172 | [
"DDInter410",
"DDInter863"
] | Clomipramine | Histamine | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | A depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. | Moderate | 1 | [
[
[
1237,
24,
172
]
],
[
[
1237,
74,
1264
],
[
1264,
24,
172
]
],
[
[
1237,
63,
1242
],
[
1242,
24,
172
]
],
[
[
1237,
24,
849
],
[
849,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histamine"
]
],
[
[
"Clomipramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when take... | Clomipramine (Compound) resembles Doxepin (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Histamine
Clomipramine may cause a moderate interaction that could exa... |
DB00374 | DB03404 | 1,061 | 765 | [
"DDInter1852",
"DDInter855"
] | Treprostinil | Hemin | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Moderate | 1 | [
[
[
1061,
24,
765
]
],
[
[
1061,
24,
840
],
[
840,
63,
765
]
],
[
[
1061,
63,
291
],
[
291,
24,
765
]
],
[
[
1061,
64,
1172
],
[
1172,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hemin"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorapaxar"
],
[
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar and Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Hemin
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Argatroban and Argatroba... |
DB08867 | DB12364 | 807 | 1,421 | [
"DDInter1897",
"DDInter200"
] | Ulipristal | Betrixaban | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Moderate | 1 | [
[
[
807,
24,
1421
]
],
[
[
807,
24,
1017
],
[
1017,
24,
1421
]
],
[
[
807,
63,
478
],
[
478,
24,
1421
]
],
[
[
807,
25,
1456
],
[
1456,
... | [
[
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
]
],
[
[
"Ulipristal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Ulipristal may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotin... |
DB00193 | DB00581 | 534 | 355 | [
"DDInter1841",
"DDInter1018"
] | Tramadol | Lactulose | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Moderate | 1 | [
[
[
534,
24,
355
]
],
[
[
534,
21,
28750
],
[
28750,
60,
355
]
],
[
[
534,
24,
286
],
[
286,
62,
355
]
],
[
[
534,
24,
79
],
[
79,
2... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
]
],
[
[
"Tramadol",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal discomfort"
],
[
"Abdominal discomfort",
"{u} (Sid... | Tramadol (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Lactulose (Compound)
Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a minor interaction that can limit clinica... |
DB01132 | DB09280 | 1,130 | 1,604 | [
"DDInter1472",
"DDInter1101"
] | Pioglitazone | Lumacaftor | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
1130,
24,
1604
]
],
[
[
1130,
24,
1060
],
[
1060,
62,
1604
]
],
[
[
1130,
63,
473
],
[
473,
24,
1604
]
],
[
[
1130,
24,
192
],
[
192,
... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
... | Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with Rep... |
DB11837 | DB11901 | 1,297 | 913 | [
"DDInter1351",
"DDInter107"
] | Osilodrostat | Apalutamide | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
1297,
25,
913
]
],
[
[
1297,
62,
112
],
[
112,
23,
913
]
],
[
[
1297,
63,
608
],
[
608,
23,
913
]
],
[
[
1297,
63,
1322
],
[
1322,
... | [
[
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and ... |
DB00865 | DB01276 | 939 | 123 | [
"DDInter187",
"DDInter706"
] | Benzphetamine | Exenatide | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
939,
24,
123
]
],
[
[
939,
63,
1636
],
[
1636,
24,
123
]
],
[
[
939,
25,
1039
],
[
1039,
24,
123
]
],
[
[
939,
24,
820
],
[
820,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Benzphetamine may lead to a major life threatening interaction when taken with Dexfenfluramine and Dexfe... |
DB08868 | DB14761 | 1,011 | 242 | [
"DDInter737",
"DDInter1578"
] | Fingolimod | Remdesivir | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which is a respiratory disease that is capable of progressing to viral pneumonia and acute respiratory distress syndrome (ARDS); COVID-19 can be fatal. Like other RNA viruses, SARS-CoV-2 depends o... | Moderate | 1 | [
[
[
1011,
24,
242
]
],
[
[
1011,
64,
1377
],
[
1377,
24,
242
]
],
[
[
1011,
25,
129
],
[
129,
24,
242
]
],
[
[
1011,
63,
267
],
[
267,
... | [
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomi... | Fingolimod may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir
Fingolimod may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a moderat... |
DB00218 | DB11921 | 1,176 | 1,019 | [
"DDInter1247",
"DDInter492"
] | Moxifloxacin | Deflazacort | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
1176,
25,
1019
]
],
[
[
1176,
24,
1193
],
[
1193,
23,
1019
]
],
[
[
1176,
25,
959
],
[
959,
24,
1019
]
],
[
[
1176,
25,
1619
],
[
1619... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Moxifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Z... | Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Moxifloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide m... |
DB00252 | DB08896 | 362 | 292 | [
"DDInter1460",
"DDInter1576"
] | Phenytoin | Regorafenib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
362,
24,
292
]
],
[
[
362,
24,
79
],
[
79,
1,
292
]
],
[
[
362,
6,
6017
],
[
6017,
45,
292
]
],
[
[
362,
21,
29276
],
[
29276,
6... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Phenytoin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Phenytoin (Compound) causes Haemoglobin (Side Effect) and Haemoglobi... |
DB00400 | DB06016 | 353 | 1,508 | [
"DDInter843",
"DDInter300"
] | Griseofulvin | Cariprazine | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
353,
24,
1508
]
],
[
[
353,
24,
1593
],
[
1593,
63,
1508
]
],
[
[
353,
24,
1213
],
[
1213,
24,
1508
]
],
[
[
353,
62,
1101
],
[
1101,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Da... |
DB11627 | DB11793 | 1,367 | 738 | [
"DDInter860",
"DDInter1297"
] | Hepatitis B Vaccine (Recombinant) | Niraparib | Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, n... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1367,
24,
738
]
],
[
[
1367,
63,
1213
],
[
1213,
24,
738
]
],
[
[
1367,
24,
1619
],
[
1619,
63,
738
]
],
[
[
1367,
24,
351
],
[
351,
... | [
[
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Hepatitis B Vaccine (Recombinant)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken ... | Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Hepatitis B Vaccine (Recombinant) may cause a moderate interaction that could exacerbate dis... |
DB00631 | DB01076 | 372 | 700 | [
"DDInter405",
"DDInter133"
] | Clofarabine | Atorvastatin | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
372,
24,
700
]
],
[
[
372,
24,
788
],
[
788,
1,
700
]
],
[
[
372,
7,
2969
],
[
2969,
46,
700
]
],
[
[
372,
18,
1917
],
[
1917,
4... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Clofarabine (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Atorvastatin (Compound)
Clofarabine (Compound) downregulates CDC25B ... |
DB01255 | DB12141 | 633 | 971 | [
"DDInter1078",
"DDInter817"
] | Lisdexamfetamine | Gilteritinib | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
633,
24,
971
]
],
[
[
633,
62,
112
],
[
112,
23,
971
]
],
[
[
633,
63,
485
],
[
485,
24,
971
]
],
[
[
633,
24,
823
],
[
823,
63,... | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
... | Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Penta... |
DB00073 | DB06688 | 1,394 | 1,430 | [
"DDInter1608",
"DDInter1677"
] | Rituximab | Sipuleucel-T | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1394,
24,
1430
]
],
[
[
1394,
24,
869
],
[
869,
24,
1430
]
],
[
[
1394,
25,
676
],
[
676,
63,
1430
]
],
[
[
1394,
24,
713
],
[
713,
... | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Rituximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may caus... |
DB01229 | DB09115 | 973 | 505 | [
"DDInter1377",
"DDInter559"
] | Paclitaxel | Diiodohydroxyquinoline | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
973,
24,
505
]
],
[
[
973,
24,
1593
],
[
1593,
24,
505
]
],
[
[
973,
63,
467
],
[
467,
24,
505
]
],
[
[
973,
25,
908
],
[
908,
2... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Simvastat... |
DB00686 | DB06209 | 383 | 256 | [
"DDInter1424",
"DDInter1508"
] | Pentosan polysulfate | Prasugrel | Pentosan polysulfate is a sulfated pentosyl polysaccharide with heparin-like properties. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversib... | Moderate | 1 | [
[
[
383,
24,
256
]
],
[
[
383,
21,
28681
],
[
28681,
60,
256
]
],
[
[
383,
24,
1479
],
[
1479,
24,
256
]
],
[
[
383,
24,
578
],
[
578,
... | [
[
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Pentosan polysulfate",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",... | Pentosan polysulfate (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction t... |
DB01254 | DB11796 | 1,213 | 1,612 | [
"DDInter484",
"DDInter786"
] | Dasatinib | Fostemsavir | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
1213,
24,
1612
]
],
[
[
1213,
63,
1051
],
[
1051,
23,
1612
]
],
[
[
1213,
24,
98
],
[
98,
23,
1612
]
],
[
[
1213,
24,
1476
],
[
1476,
... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem a... |
DB05812 | DB12332 | 1,374 | 1,619 | [
"DDInter8",
"DDInter1626"
] | Abiraterone | Rucaparib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1374,
24,
1619
]
],
[
[
1374,
62,
112
],
[
112,
23,
1619
]
],
[
[
1374,
23,
1135
],
[
1135,
23,
1619
]
],
[
[
1374,
24,
154
],
[
154,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Abiraterone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Abiraterone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxe... |
DB01177 | DB04844 | 77 | 843 | [
"DDInter904",
"DDInter1778"
] | Idarubicin | Tetrabenazine | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008. | Moderate | 1 | [
[
[
77,
24,
843
]
],
[
[
77,
63,
479
],
[
479,
40,
843
]
],
[
[
77,
6,
12523
],
[
12523,
45,
843
]
],
[
[
77,
18,
3771
],
[
3771,
46... | [
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil (Compound) resembles Tetrabenazine (Compound)
Idarubicin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Tetrabenazine (Compound)
Idarubicin (Compound) downregulates SUV39H1 (Gene) and SUV39H1... |
DB09098 | DB11791 | 98 | 785 | [
"DDInter1700",
"DDInter287"
] | Somatrem | Capmatinib | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate. Such discussion revolves around whether patients' natural dispo... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
98,
24,
785
]
],
[
[
98,
63,
837
],
[
837,
23,
785
]
],
[
[
98,
63,
868
],
[
868,
24,
785
]
],
[
[
98,
24,
1320
],
[
1320,
63,
... | [
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
... | Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemuraf... |
DB09330 | DB14575 | 985 | 733 | [
"DDInter1352",
"DDInter674"
] | Osimertinib | Eslicarbazepine | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
985,
24,
733
]
],
[
[
985,
63,
1101
],
[
1101,
23,
733
]
],
[
[
985,
62,
168
],
[
168,
23,
733
]
],
[
[
985,
64,
1264
],
[
1264,
... | [
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Osimertinib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bor... |
DB00747 | DB01136 | 1,442 | 772 | [
"DDInter1647",
"DDInter305"
] | Scopolamine | Carvedilol | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
1442,
24,
772
]
],
[
[
1442,
6,
4973
],
[
4973,
45,
772
]
],
[
[
1442,
21,
28817
],
[
28817,
60,
772
]
],
[
[
1442,
63,
475
],
[
475,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Scopolamine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",... | Scopolamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carvedilol (Compound)
Scopolamine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Carvedilol (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine... |
DB00207 | DB00694 | 1,570 | 51 | [
"DDInter157",
"DDInter485"
] | Azithromycin | Daunorubicin | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Moderate | 1 | [
[
[
1570,
24,
51
]
],
[
[
1570,
6,
7950
],
[
7950,
45,
51
]
],
[
[
1570,
7,
9242
],
[
9242,
46,
51
]
],
[
[
1570,
21,
28644
],
[
28644,
... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compo... | Azithromycin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound)
Azithromycin (Compound) upregulates WDR7 (Gene) and WDR7 (Gene) is upregulated by Daunorubicin (Compound)
Azithromycin (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Daunorubicin (Compound)
... |
DB01218 | DB01319 | 1,493 | 34 | [
"DDInter852",
"DDInter777"
] | Halofantrine | Fosamprenavir | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Major | 2 | [
[
[
1493,
25,
34
]
],
[
[
1493,
64,
1091
],
[
1091,
40,
34
]
],
[
[
1493,
6,
8374
],
[
8374,
45,
34
]
],
[
[
1493,
21,
29106
],
[
29106,
... | [
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
... | Halofantrine may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Halofantrine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Halofantrine (Compound) causes Myalgia (Side Effect) and Myalgia (Side ... |
DB01285 | DB15091 | 708 | 676 | [
"DDInter445",
"DDInter1901"
] | Corticotropin | Upadacitinib | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
708,
25,
676
]
],
[
[
708,
24,
1430
],
[
1430,
24,
676
]
],
[
[
708,
63,
122
],
[
122,
24,
676
]
],
[
[
708,
64,
932
],
[
932,
2... | [
[
[
"Corticotropin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"... | Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib
Corticotropin may cause a moderate interaction that could exacerbate diseases when taken with Verapamil... |
DB08865 | DB13139 | 1,593 | 1,032 | [
"DDInter448",
"DDInter1063"
] | Crizotinib | Levosalbutamol | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1593,
24,
1032
]
],
[
[
1593,
63,
1220
],
[
1220,
23,
1032
]
],
[
[
1593,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
1593,
64,
594
],
[
594... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Crizotinib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantini... |
DB00585 | DB09143 | 1,127 | 313 | [
"DDInter1309",
"DDInter1701"
] | Nizatidine | Sonidegib | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Minor | 0 | [
[
[
1127,
23,
313
]
],
[
[
1127,
1,
1194
],
[
1194,
23,
313
]
],
[
[
1127,
24,
478
],
[
478,
24,
313
]
],
[
[
1127,
25,
1213
],
[
1213,
... | [
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sonidegib"
]
],
[
[
"Nizatidine",
"{u} (Compound) resembles {v} (Compound)",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor inte... | Nizatidine (Compound) resembles Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Sonidegib
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exac... |
DB01254 | DB13139 | 1,213 | 1,032 | [
"DDInter484",
"DDInter1063"
] | Dasatinib | Levosalbutamol | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
1213,
24,
1032
]
],
[
[
1213,
63,
1573
],
[
1573,
23,
1032
]
],
[
[
1213,
64,
1220
],
[
1220,
23,
1032
]
],
[
[
1213,
25,
1618
],
[
16... | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Dasatinib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may ... |
DB00486 | DB01209 | 1,614 | 1,359 | [
"DDInter1253",
"DDInter531"
] | Nabilone | Dezocine | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
1614,
24,
1359
]
],
[
[
1614,
24,
234
],
[
234,
1,
1359
]
],
[
[
1614,
24,
717
],
[
717,
24,
1359
]
],
[
[
1614,
63,
1594
],
[
1594,
... | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
],
[
"... | Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interaction ... |
DB00460 | DB00992 | 612 | 842 | [
"DDInter1929",
"DDInter1182"
] | Verteporfin | Methyl aminolevulinate (topical) | Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 n... | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
612,
24,
842
]
],
[
[
612,
21,
28787
],
[
28787,
60,
842
]
],
[
[
612,
24,
1274
],
[
1274,
24,
842
]
],
[
[
612,
24,
820
],
[
820,
... | [
[
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Verteporfin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side... | Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Verteporfin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Methyl aminolevulinate (Compound)
Verteporfin may cause a moderate interaction that could exacerbate disease... |
DB00390 | DB00443 | 1,252 | 251 | [
"DDInter554",
"DDInter195"
] | Digoxin | Betamethasone | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Moderate | 1 | [
[
[
1252,
24,
251
]
],
[
[
1252,
24,
870
],
[
870,
1,
251
]
],
[
[
1252,
24,
1486
],
[
1486,
40,
251
]
],
[
[
1252,
6,
8374
],
[
8374,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Betamethasone (Compound)
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compound) resembles... |
DB00418 | DB01114 | 536 | 272 | [
"DDInter1650",
"DDInter362"
] | Secobarbital | Chlorpheniramine | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
536,
24,
272
]
],
[
[
536,
24,
849
],
[
849,
63,
272
]
],
[
[
536,
63,
128
],
[
128,
24,
272
]
],
[
[
536,
21,
28898
],
[
28898,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Dexbromphen... |
DB00004 | DB00685 | 669 | 1,299 | [
"DDInter499",
"DDInter1887"
] | Denileukin diftitox | Trovafloxacin | A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system. | Trovafloxacin is a broad spectrum antibiotic that has been commonly marketed under the brand name Trovan by Pfizer. It exerts its antibacterial activity by inhibiting the uncoiling of supercoiled DNA in various bacteria by blocking the activity of DNA gyrase and topoisomerase IV. It was shown to be more effective again... | Minor | 0 | [
[
[
669,
23,
1299
]
],
[
[
669,
23,
872
],
[
872,
40,
1299
]
],
[
[
669,
24,
384
],
[
384,
63,
1299
]
],
[
[
669,
25,
1377
],
[
1377,
... | [
[
[
"Denileukin diftitox",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trovafloxacin"
]
],
[
[
"Denileukin diftitox",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxac... | Denileukin diftitox may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Trovafloxacin (Compound)
Denileukin diftitox may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate... |
DB00719 | DB00782 | 1,219 | 1,123 | [
"DDInter149",
"DDInter1535"
] | Azatadine | Propantheline | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
1219,
24,
1123
]
],
[
[
1219,
24,
551
],
[
551,
23,
1123
]
],
[
[
1219,
24,
768
],
[
768,
63,
1123
]
],
[
[
1219,
63,
684
],
[
684,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine may cause a minor interaction that can limit clinical effects when taken with Propantheline
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol and Tapenta... |
DB00850 | DB01132 | 1,630 | 1,130 | [
"DDInter1432",
"DDInter1472"
] | Perphenazine | Pioglitazone | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1630,
24,
1130
]
],
[
[
1630,
6,
12523
],
[
12523,
45,
1130
]
],
[
[
1630,
21,
28778
],
[
28778,
60,
1130
]
],
[
[
1630,
1,
851
],
[
8... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Perphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compo... | Perphenazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Pioglitazone (Compound)
Perphenazine (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Pioglitazone (Compound)
Perphenazine (Compound) resembles Nefazodone (Compound) and Nefazodone may cause a m... |
DB00480 | DB14730 | 1,668 | 1,412 | [
"DDInter1035",
"DDInter264"
] | Lenalidomide | Calaspargase pegol | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1668,
24,
1412
]
],
[
[
1668,
63,
322
],
[
322,
24,
1412
]
],
[
[
1668,
25,
888
],
[
888,
24,
1412
]
],
[
[
1668,
24,
850
],
[
850,
... | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Lenalidomide may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen ... |
DB00812 | DB01082 | 998 | 1,448 | [
"DDInter1451",
"DDInter1713"
] | Phenylbutazone | Streptomycin | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit conside... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
998,
24,
1448
]
],
[
[
998,
6,
10612
],
[
10612,
45,
1448
]
],
[
[
998,
62,
608
],
[
608,
23,
1448
]
],
[
[
998,
24,
1272
],
[
1272,
... | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} ... | Phenylbutazone (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Streptomycin (Compound)
Phenylbutazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Streptomycin
Phenylbuta... |
DB06168 | DB14444 | 1,531 | 151 | [
"DDInter281",
"DDInter924"
] | Canakinumab | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
1531,
24,
151
]
],
[
[
1531,
63,
66
],
[
66,
24,
151
]
],
[
[
1531,
24,
1619
],
[
1619,
24,
151
]
],
[
[
1531,
25,
375
],
[
375,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Canakinumab may cause a moderate int... |
DB00307 | DB00495 | 1,101 | 139 | [
"DDInter202",
"DDInter1961"
] | Bexarotene | Zidovudine | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Major | 2 | [
[
[
1101,
25,
139
]
],
[
[
1101,
25,
231
],
[
231,
40,
139
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
139
]
],
[
[
1101,
21,
29209
],
[
29209,
... | [
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stavudine"
],
[
"Stavudine",
"{u} (Co... | Bexarotene may lead to a major life threatening interaction when taken with Stavudine and Stavudine (Compound) resembles Zidovudine (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zidovudine (Compound)
Bexarotene (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is c... |
DB00598 | DB06703 | 1,523 | 619 | [
"DDInter1013",
"DDInter793"
] | Labetalol | Gadobutrol | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to ot... | Moderate | 1 | [
[
[
1523,
24,
619
]
],
[
[
1523,
21,
28810
],
[
28810,
60,
619
]
],
[
[
1523,
24,
1013
],
[
1013,
63,
619
]
],
[
[
1523,
21,
28810
],
[
28... | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobutrol"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u}... | Labetalol (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Gadobutrol (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Tyropanoic acid and Tyropanoic acid may cause a moderate interaction that could exacerbate ... |
DB00022 | DB00069 | 268 | 367 | [
"DDInter1408",
"DDInter946"
] | Peginterferon alfa-2b | Interferon alfacon-1 | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Interferon alfacon-1 is a recombinant non-naturally occurring type-I interferon. The 166-amino acid sequence of Interferon alfacon-1 was derived by scanning the sequences of several natural interferon alpha subtypes and assigning the most frequently observed amino acid in each corresponding position. Four additional am... | Moderate | 1 | [
[
[
268,
24,
367
]
],
[
[
268,
23,
450
],
[
450,
62,
367
]
],
[
[
268,
24,
467
],
[
467,
63,
367
]
],
[
[
268,
24,
305
],
[
305,
24,... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
... | Peginterferon alfa-2b may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Interferon alfacon-1
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseas... |
DB00321 | DB12130 | 21 | 1,017 | [
"DDInter78",
"DDInter1094"
] | Amitriptyline | Lorlatinib | Amitriptyline is a tricyclic antidepressant that has been used to treat depression for decades. ELAVIL, a previously approved branded product of amitriptyline, was first approved by the FDA in 1961. Amitriptyline has been investigated in the treatment of pain-related conditions, attributed to its analgesic properties. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
21,
24,
1017
]
],
[
[
21,
24,
590
],
[
590,
24,
1017
]
],
[
[
21,
25,
11
],
[
11,
24,
1017
]
],
[
[
21,
24,
971
],
[
971,
63,
... | [
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],... | Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Amitriptyline may lead to a major life threatening interaction when taken with Toremifene and Toremifen... |
DB00836 | DB11718 | 543 | 927 | [
"DDInter1088",
"DDInter640"
] | Loperamide | Encorafenib | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
543,
24,
927
]
],
[
[
543,
24,
112
],
[
112,
23,
927
]
],
[
[
543,
63,
216
],
[
216,
24,
927
]
],
[
[
543,
24,
495
],
[
495,
24,... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine a... |
DB00991 | DB08880 | 97 | 1,510 | [
"DDInter1358",
"DDInter1771"
] | Oxaprozin | Teriflunomide | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
97,
25,
1510
]
],
[
[
97,
63,
1144
],
[
1144,
24,
1510
]
],
[
[
97,
62,
752
],
[
752,
24,
1510
]
],
[
[
97,
75,
126
],
[
126,
24... | [
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglin... | Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Oxaprozin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimet... |
DB01332 | DB09268 | 731 | 1,662 | [
"DDInter332",
"DDInter1464"
] | Ceftizoxime | Picosulfuric acid | A semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms. It has few side effects and is reported to b... | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
731,
24,
1662
]
],
[
[
731,
63,
597
],
[
597,
24,
1662
]
],
[
[
731,
1,
1403
],
[
1403,
24,
1662
]
],
[
[
731,
40,
1453
],
[
1453,
... | [
[
[
"Ceftizoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Ceftizoxime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
... | Ceftizoxime may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ceftizoxime (Compound) resembles Cefepime (Compound) and Cefepime may cause a moderate interac... |
DB00773 | DB11791 | 896 | 785 | [
"DDInter702",
"DDInter287"
] | Etoposide | Capmatinib | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
896,
24,
785
]
],
[
[
896,
24,
310
],
[
310,
24,
785
]
],
[
[
896,
63,
482
],
[
482,
24,
785
]
],
[
[
896,
24,
1320
],
[
1320,
6... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tiogua... |
DB00328 | DB01249 | 831 | 258 | [
"DDInter921",
"DDInter958"
] | Indomethacin | Iodixanol | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents. | Major | 2 | [
[
[
831,
25,
258
]
],
[
[
831,
25,
497
],
[
497,
1,
258
]
],
[
[
831,
21,
28748
],
[
28748,
60,
258
]
],
[
[
831,
24,
712
],
[
712,
... | [
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
]
],
[
[
"Indomethacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} (Com... | Indomethacin may lead to a major life threatening interaction when taken with Iohexol and Iohexol (Compound) resembles Iodixanol (Compound)
Indomethacin (Compound) causes Vertigo (Side Effect) and Vertigo (Side Effect) is caused by Iodixanol (Compound)
Indomethacin may cause a moderate interaction that could exacerbate... |
DB00443 | DB01396 | 251 | 1,482 | [
"DDInter195",
"DDInter553"
] | Betamethasone | Digitoxin | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Moderate | 1 | [
[
[
251,
24,
1482
]
],
[
[
251,
63,
1252
],
[
1252,
1,
1482
]
],
[
[
251,
6,
8374
],
[
8374,
45,
1482
]
],
[
[
251,
7,
2719
],
[
2719,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin (Compound) resembles Digitoxin (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Digitoxin (Compound)
Betamethasone (Compound) upregulates ATP1A1 (Gene) and ATP1A1 (Gene)... |
DB00312 | DB08901 | 1,023 | 1,468 | [
"DDInter1423",
"DDInter1492"
] | Pentobarbital | Ponatinib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1023,
24,
1468
]
],
[
[
1023,
24,
478
],
[
478,
24,
1468
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
1468
]
],
[
[
1023,
7,
3072
],
[
3072,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ponatinib (Compound)
Pentobarbital (C... |
DB00400 | DB08867 | 353 | 807 | [
"DDInter843",
"DDInter1897"
] | Griseofulvin | Ulipristal | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
353,
24,
807
]
],
[
[
353,
24,
1135
],
[
1135,
62,
807
]
],
[
[
353,
24,
723
],
[
723,
23,
807
]
],
[
[
353,
24,
792
],
[
792,
2... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepi... |
DB00554 | DB09054 | 1,027 | 384 | [
"DDInter1478",
"DDInter905"
] | Piroxicam | Idelalisib | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1027,
24,
384
]
],
[
[
1027,
24,
222
],
[
222,
23,
384
]
],
[
[
1027,
25,
1618
],
[
1618,
24,
384
]
],
[
[
1027,
63,
305
],
[
305,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
... | Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Piroxicam may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may caus... |
DB06603 | DB08913 | 39 | 1,186 | [
"DDInter1387",
"DDInter1561"
] | Panobinostat | Radium Ra 223 dichloride | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
39,
24,
1186
]
],
[
[
39,
64,
1491
],
[
1491,
24,
1186
]
],
[
[
39,
25,
1619
],
[
1619,
63,
1186
]
],
[
[
39,
63,
372
],
[
372,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
... | Panobinostat may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Panobinostat may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cau... |
DB00063 | DB00461 | 366 | 598 | [
"DDInter659",
"DDInter1254"
] | Eptifibatide | Nabumetone | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Moderate | 1 | [
[
[
366,
24,
598
]
],
[
[
366,
64,
1271
],
[
1271,
24,
598
]
],
[
[
366,
24,
1512
],
[
1512,
63,
598
]
],
[
[
366,
25,
936
],
[
936,
... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabumetone"
]
],
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alteplase"
],
[
"Altepla... | Eptifibatide may lead to a major life threatening interaction when taken with Alteplase and Alteplase may cause a moderate interaction that could exacerbate diseases when taken with Nabumetone
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may caus... |
DB00831 | DB09278 | 1,178 | 852 | [
"DDInter1866",
"DDInter24"
] | Trifluoperazine | Activated charcoal | A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic. | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Moderate | 1 | [
[
[
1178,
24,
852
]
],
[
[
1178,
63,
127
],
[
127,
24,
852
]
],
[
[
1178,
24,
1411
],
[
1411,
24,
852
]
],
[
[
1178,
40,
1630
],
[
1630,
... | [
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Trifluoperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"... | Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Trifluoperazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbuta... |
DB00637 | DB12825 | 1,557 | 1,375 | [
"DDInter128",
"DDInter1032"
] | Astemizole | Lefamulin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Major | 2 | [
[
[
1557,
25,
1375
]
],
[
[
1557,
23,
112
],
[
112,
23,
1375
]
],
[
[
1557,
24,
159
],
[
159,
63,
1375
]
],
[
[
1557,
63,
1101
],
[
1101,
... | [
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Astemizole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lefamulin
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and La... |
DB01037 | DB01067 | 1,161 | 959 | [
"DDInter1653",
"DDInter826"
] | Selegiline | Glipizide | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
1161,
24,
959
]
],
[
[
1161,
63,
245
],
[
245,
40,
959
]
],
[
[
1161,
24,
1411
],
[
1411,
1,
959
]
],
[
[
1161,
6,
8374
],
[
8374,
... | [
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB00446 | DB01041 | 597 | 770 | [
"DDInter351",
"DDInter1789"
] | Chloramphenicol | Thalidomide | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
597,
24,
770
]
],
[
[
597,
24,
1668
],
[
1668,
1,
770
]
],
[
[
597,
6,
7524
],
[
7524,
45,
770
]
],
[
[
597,
21,
28784
],
[
28784,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide (Compound) resembles Thalidomide (Compound)
Chloramphenicol (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Chloramphenicol (Compound) causes Thrombocytopenia... |
DB00619 | DB10276 | 1,419 | 1,624 | [
"DDInter909",
"DDInter1623"
] | Imatinib | Rotavirus vaccine | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
1419,
25,
1624
]
],
[
[
1419,
24,
617
],
[
617,
24,
1624
]
],
[
[
1419,
63,
552
],
[
552,
25,
1624
]
],
[
[
1419,
24,
1307
],
[
1307,
... | [
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budeson... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Car... |
DB00782 | DB00985 | 1,123 | 1,443 | [
"DDInter1535",
"DDInter562"
] | Propantheline | Dimenhydrinate | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Dimehydrinate was first described in the literature in 1949, and patented in 1950. Early research into dimenhydrinate focused on its role as an antihistamine for urticaria; the treatment of motion sickness was an accidental discovery. Dimenhydrinate, also known as B-dimethylaminoethyl benzohydrol ether 8-chlorotheophyl... | Moderate | 1 | [
[
[
1123,
24,
1443
]
],
[
[
1123,
24,
1376
],
[
1376,
63,
1443
]
],
[
[
1123,
63,
357
],
[
357,
1,
1443
]
],
[
[
1123,
24,
358
],
[
358,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimenhydrinate"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dimenhydrinate
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with B... |
DB01240 | DB06441 | 885 | 936 | [
"DDInter657",
"DDInter283"
] | Epoprostenol | Cangrelor | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Moderate | 1 | [
[
[
885,
24,
936
]
],
[
[
885,
23,
944
],
[
944,
62,
936
]
],
[
[
885,
63,
97
],
[
97,
24,
936
]
],
[
[
885,
24,
643
],
[
643,
63,
... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
... | Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Cangrelor
Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin and Oxaprozin ... |
DB11901 | DB12893 | 913 | 586 | [
"DDInter107",
"DDInter1629"
] | Apalutamide | Sacituzumab govitecan | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements. It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resi... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Major | 2 | [
[
[
913,
25,
586
]
],
[
[
913,
63,
869
],
[
869,
24,
586
]
],
[
[
913,
64,
384
],
[
384,
24,
586
]
],
[
[
913,
25,
1017
],
[
1017,
2... | [
[
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Apalutamide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib... |
DB00678 | DB00741 | 240 | 167 | [
"DDInter1095",
"DDInter885"
] | Losartan | Hydrocortisone | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
240,
24,
167
]
],
[
[
240,
24,
1220
],
[
1220,
40,
167
]
],
[
[
240,
63,
175
],
[
175,
40,
167
]
],
[
[
240,
24,
870
],
[
870,
1... | [
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Losartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[... | Losartan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Losartan may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Hydrocorti... |
DB00582 | DB00969 | 1,622 | 2 | [
"DDInter1946",
"DDInter52"
] | Voriconazole | Alosetron | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Moderate | 1 | [
[
[
1622,
24,
2
]
],
[
[
1622,
6,
6017
],
[
6017,
45,
2
]
],
[
[
1622,
21,
28883
],
[
28883,
60,
2
]
],
[
[
1622,
25,
1362
],
[
1362,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alosetron"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound... | Voriconazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Alosetron (Compound)
Voriconazole (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Alosetron (Compound)
Voriconazole may lead to a major life threatening interaction when taken with Olaparib and Olaparib ... |
DB00196 | DB04953 | 600 | 495 | [
"DDInter743",
"DDInter708"
] | Fluconazole | Ezogabine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
600,
24,
495
]
],
[
[
600,
21,
28997
],
[
28997,
60,
495
]
],
[
[
600,
25,
1135
],
[
1135,
62,
495
]
],
[
[
600,
23,
112
],
[
112,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Fluconazole",
"{u} (Compound) causes {v} (Side Effect)",
"Ill-defined disorder"
],
[
"Ill-defined disorder",
"{u... | Fluconazole (Compound) causes Ill-defined disorder (Side Effect) and Ill-defined disorder (Side Effect) is caused by Ezogabine (Compound)
Fluconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ezo... |
DB00188 | DB00252 | 168 | 362 | [
"DDInter222",
"DDInter1460"
] | Bortezomib | Phenytoin | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Major | 2 | [
[
[
168,
25,
362
]
],
[
[
168,
23,
307
],
[
307,
1,
362
]
],
[
[
168,
25,
759
],
[
759,
40,
362
]
],
[
[
168,
23,
126
],
[
126,
63,
... | [
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenytoin"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Bortezomib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Phenytoin (Compound)
Bortezomib may lead to a major life threatening interaction when taken with Primidone and Primidone (Compound) resembles Phenytoin (Compound)
Bortezomib may cause a ... |
DB06810 | DB11793 | 397 | 738 | [
"DDInter1484",
"DDInter1297"
] | Plicamycin | Niraparib | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
397,
24,
738
]
],
[
[
397,
64,
1213
],
[
1213,
24,
738
]
],
[
[
397,
63,
1253
],
[
1253,
24,
738
]
],
[
[
397,
24,
496
],
[
496,
... | [
[
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Plicamycin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a m... |
DB00405 | DB00532 | 128 | 208 | [
"DDInter517",
"DDInter1152"
] | Dexbrompheniramine | Mephenytoin | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Moderate | 1 | [
[
[
128,
24,
208
]
],
[
[
128,
63,
1242
],
[
1242,
24,
208
]
],
[
[
128,
24,
1219
],
[
1219,
63,
208
]
],
[
[
128,
24,
530
],
[
530,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Azat... |
DB06595 | DB09045 | 1,491 | 52 | [
"DDInter1214",
"DDInter607"
] | Midostaurin | Dulaglutide | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
1491,
24,
52
]
],
[
[
1491,
63,
170
],
[
170,
23,
52
]
],
[
[
1491,
64,
609
],
[
609,
24,
52
]
],
[
[
1491,
25,
1154
],
[
1154,
... | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Midostaurin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin... |
DB00087 | DB01281 | 599 | 881 | [
"DDInter41",
"DDInter5"
] | Alemtuzumab | Abatacept | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Moderate | 1 | [
[
[
599,
24,
881
]
],
[
[
599,
24,
4
],
[
4,
63,
881
]
],
[
[
599,
24,
66
],
[
66,
24,
881
]
],
[
[
599,
63,
1184
],
[
1184,
24,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abatacept"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Abatacept
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when t... |
DB00581 | DB11921 | 355 | 1,019 | [
"DDInter1018",
"DDInter492"
] | Lactulose | Deflazacort | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
355,
24,
1019
]
],
[
[
355,
63,
443
],
[
443,
24,
1019
]
],
[
[
355,
24,
1326
],
[
1326,
24,
1019
]
],
[
[
355,
23,
286
],
[
286,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Spironolactone"
],
[... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Spironolactone and Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide ... |
DB00691 | DB09146 | 1,058 | 489 | [
"DDInter1237",
"DDInter978"
] | Moexipril | Iron sucrose | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, ir... | Moderate | 1 | [
[
[
1058,
24,
489
]
],
[
[
1058,
1,
664
],
[
664,
24,
489
]
],
[
[
1058,
40,
610
],
[
610,
24,
489
]
],
[
[
1058,
1,
664
],
[
664,
4... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Moexipril",
"{u} (Compound) resembles {v} (Compound)",
"Perindopril"
],
[
"Perindopril",
"{u} may cause a moder... | Moexipril (Compound) resembles Perindopril (Compound) and Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Moexipril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Iron sucros... |
DB00011 | DB00250 | 1,451 | 10 | [
"DDInter944",
"DDInter475"
] | Interferon alfa-n1 | Dapsone | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Moderate | 1 | [
[
[
1451,
24,
10
]
],
[
[
1451,
24,
4
],
[
4,
63,
10
]
],
[
[
1451,
24,
581
],
[
581,
24,
10
]
],
[
[
1451,
25,
1510
],
[
1510,
63,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapsone"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine me... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dapsone
Interferon alfa-n1 may cause a moderate interaction that could exacerbate dis... |
DB00402 | DB01128 | 1,407 | 918 | [
"DDInter685",
"DDInter204"
] | Eszopiclone | Bicalutamide | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Moderate | 1 | [
[
[
1407,
24,
918
]
],
[
[
1407,
24,
129
],
[
129,
40,
918
]
],
[
[
1407,
6,
8374
],
[
8374,
45,
918
]
],
[
[
1407,
21,
29666
],
[
29666,
... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide (Compound) resembles Bicalutamide (Compound)
Eszopiclone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bicalutamide (Compound)
Eszopiclone (Compound) causes Melaena (Side Effect) and ... |
DB00580 | DB06441 | 311 | 936 | [
"DDInter1910",
"DDInter283"
] | Valdecoxib | Cangrelor | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an act... | Moderate | 1 | [
[
[
311,
24,
936
]
],
[
[
311,
24,
477
],
[
477,
24,
936
]
],
[
[
311,
63,
305
],
[
305,
24,
936
]
],
[
[
311,
63,
1271
],
[
1271,
2... | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cangrelor"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
... | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Cangrelor
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherich... |
DB00470 | DB14575 | 530 | 733 | [
"DDInter601",
"DDInter674"
] | Dronabinol | Eslicarbazepine | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
530,
24,
733
]
],
[
[
530,
24,
1264
],
[
1264,
24,
733
]
],
[
[
530,
1,
1614
],
[
1614,
24,
733
]
],
[
[
530,
63,
1594
],
[
1594,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exac... |
DB01263 | DB11581 | 859 | 1,456 | [
"DDInter1494",
"DDInter1926"
] | Posaconazole | Venetoclax | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
859,
25,
1456
]
],
[
[
859,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
859,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
859,
24,
466
],
[
466,
... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u}... | Posaconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Posaconazole may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate inte... |
DB00352 | DB01095 | 482 | 671 | [
"DDInter1814",
"DDInter769"
] | Tioguanine | Fluvastatin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
482,
24,
671
]
],
[
[
482,
24,
788
],
[
788,
40,
671
]
],
[
[
482,
24,
14
],
[
14,
63,
671
]
],
[
[
482,
21,
28658
],
[
28658,
6... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction t... |
DB00013 | DB08901 | 1,255 | 1,468 | [
"DDInter1905",
"DDInter1492"
] | Urokinase | Ponatinib | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1255,
25,
1468
]
],
[
[
1255,
24,
1230
],
[
1230,
24,
1468
]
],
[
[
1255,
24,
41
],
[
41,
63,
1468
]
],
[
[
1255,
25,
4
],
[
4,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levo... |
DB00445 | DB00983 | 322 | 480 | [
"DDInter655",
"DDInter776"
] | Epirubicin | Formoterol | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
322,
24,
480
]
],
[
[
322,
24,
1148
],
[
1148,
63,
480
]
],
[
[
322,
24,
1523
],
[
1523,
25,
480
]
],
[
[
322,
18,
5998
],
[
5998,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Lab... |
DB09030 | DB12130 | 840 | 1,017 | [
"DDInter1945",
"DDInter1094"
] | Vorapaxar | Lorlatinib | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
840,
24,
1017
]
],
[
[
840,
25,
1421
],
[
1421,
63,
1017
]
],
[
[
840,
64,
126
],
[
126,
24,
1017
]
],
[
[
840,
24,
1427
],
[
1427,
... | [
[
[
"Vorapaxar",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",... | Vorapaxar may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Vorapaxar may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interactio... |
DB00445 | DB00627 | 322 | 265 | [
"DDInter655",
"DDInter1286"
] | Epirubicin | Niacin | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Moderate | 1 | [
[
[
322,
24,
265
]
],
[
[
322,
7,
11074
],
[
11074,
46,
265
]
],
[
[
322,
18,
9205
],
[
9205,
57,
265
]
],
[
[
322,
21,
29169
],
[
29169,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Epirubicin",
"{u} (Compound) upregulates {v} (Gene)",
"HERC6"
],
[
"HERC6",
"{u} (Gene) is upregulated by {v} (Compo... | Epirubicin (Compound) upregulates HERC6 (Gene) and HERC6 (Gene) is upregulated by Niacin (Compound)
Epirubicin (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Niacin (Compound)
Epirubicin (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Niacin (Compound)
Epirub... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.